Infliximab (Remsima SC®). HTA ID: 20012

Assessment Status Rapid Review Complete
HTA ID 20012
Drug Infliximab
Brand Remsima SC®
Indication In combination with methotrexate, is indicated in rheumatoid arthritis for the reduction of signs and symptoms as well as the improvement in physical function in: adult patients with active disease when the response to disease modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate; adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.
Assessment Process
Rapid review commissioned 04/03/2020
Rapid review completed 24/03/2020
Rapid review outcome A full HTA is not recommended. The NCPE recommends that infliximab SC not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.